Dr. Nathan Bryson

Developer and provider of psychedelic therapies Field Trip Health Ltd. has announced the first successful dosing of a Phase 1 clinical trial on it's proprietary psychedelic molecule. The Phase 1 trial is a double-blind, randomized, placebo-controlled study investigating the safety,...

On Tuesday, three public companies in the psychedelics/biotech space announced significant milestones in their drug development pipelines. Field Trip Receives Notice Of Patent Allowance For Proprietary Psychedelic Molecule Field Trip Health (NASDAQ: FTRP) received a notice of allowance for a US...